{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:42:22Z","timestamp":1789688542796,"version":"4.0.1"},"reference-count":450,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201146","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:49:10Z","timestamp":1770450550000},"page":"201146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted therapies in pediatric oncology: A start"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3766-3572","authenticated-orcid":false,"given":"Nilay","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201146_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/blood.V37.3.272.272","article-title":"Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia","volume":"37","author":"Aur","year":"1971","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/1097-0142(196310)16:10<1302::AID-CNCR2820161011>3.0.CO;2-A","article-title":"Vincristine in the Treatment of Acute Leukemia in Children","volume":"16","author":"Evans","year":"1963","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-3476(74)80574-3","article-title":"The impact of chemotherapy on advanced neuroblastoma. Survival of patients diagnosed in 1956, 1962, and 1966-68 in Children's Cancer Study Group A","volume":"84","author":"Leikin","year":"1974","journal-title":"J. Pediatr."},{"key":"10.1016\/j.omton.2026.201146_bib5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jama.1964.03070080042016","article-title":"Chemotherapy of Localized Inoperable Malignant Tumors of Children. Preliminary Report","volume":"189","author":"James","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2026.201146_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201146_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4049\/jimmunol.137.3.830","article-title":"Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3","volume":"137","author":"Chatenoud","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib10","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: an evolving nomenclature system","volume":"14","author":"Guimaraes Koch","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.omton.2026.201146_bib12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0140-6736(05)70493-1","article-title":"Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders","volume":"352","author":"Faye","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib13","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/annonc\/mdh093","article-title":"Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study","volume":"15","author":"Jermann","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib15","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report","volume":"12","author":"Gross","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.omton.2026.201146_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1365-2141.2011.08681.x","article-title":"Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III\/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report","volume":"153","author":"Shiramizu","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201146_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib18","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib19","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910390113","article-title":"Shedding of GD2 ganglioside by human neuroblastoma","volume":"39","author":"Ladisch","year":"1987","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib22","first-page":"5914","article-title":"Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients","volume":"44","author":"Schulz","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib23","first-page":"440","article-title":"Expression of GD2 ganglioside by untreated primary human neuroblastomas","volume":"46","author":"Wu","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib24","first-page":"5377","article-title":"Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma","volume":"47","author":"Heiner","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib25","first-page":"183","article-title":"Neuroectoderm-associated antigens on Ewing's sarcoma cell lines","volume":"47","author":"Lipinski","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib26","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1073\/pnas.83.20.7893","article-title":"Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin","volume":"83","author":"Honsik","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib27","first-page":"5969","article-title":"Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow","volume":"45","author":"Saarinen","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib28","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","article-title":"Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma","volume":"5","author":"Cheung","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib29","first-page":"2857","article-title":"Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18","volume":"49","author":"Mujoo","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib30","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4049\/jimmunol.144.4.1382","article-title":"Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody","volume":"144","author":"Mueller","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1055\/s-2005-836518","article-title":"Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy","volume":"217","author":"Simon","year":"2005","journal-title":"Klin. P\u00e4diatr."},{"key":"10.1016\/j.omton.2026.201146_bib32","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.1998.16.6.2169","article-title":"Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma","volume":"16","author":"Yu","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00002371-199605000-00005","article-title":"Phase Ia\/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma","volume":"19","author":"Murray","year":"1996","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib34","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2000.18.24.4077","volume":"18","author":"Ozkaynak","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2006.10.3564","article-title":"Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group","volume":"27","author":"Gilman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib37","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib38","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"2012","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201146_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1358331","article-title":"Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival","volume":"6","author":"Cheung","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201146_bib41","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2010.28.3317","article-title":"Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study","volume":"29","author":"Kushner","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib42","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201146_bib43","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.21.01375","article-title":"Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A","volume":"40","author":"Furman","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib44","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194837","article-title":"Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes","volume":"15","author":"Munoz","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201146_bib46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib48","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib49","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib50","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib51","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib52","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29188","article-title":"Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force","volume":"68","author":"Whittle","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201146_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib56","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.4049\/jimmunol.2200591","article-title":"Overview of CD70 as a Potential Therapeutic Target for Osteosarcoma","volume":"211","author":"Rav","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib57","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.2024025440","article-title":"A TIM-3-Fc decoy secreted by engineered T cells improves CD19 CAR T-cell therapy in B-cell acute lymphoblastic leukemia","volume":"145","author":"Falgas","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177413","article-title":"Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma","volume":"134","author":"Tripathi","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201146_bib59","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ccell.2023.09.001","article-title":"TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory","volume":"41","author":"Ausejo-Mauleon","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201146_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010239","article-title":"TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant","volume":"13","author":"Quamine","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noag025","article-title":"Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma","author":"Timpanaro","year":"2026","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.omton.2026.201146_bib63","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib64","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2767-9764.CRC-25-0293","article-title":"A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3-Expressing Relapsed or Refractory Solid Tumors","volume":"5","author":"DeSantes","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.omton.2026.201146_bib65","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1158\/1078-0432.CCR-20-4221","article-title":"The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models","volume":"27","author":"Kendsersky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib66","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"Sievers","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib67","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib68","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/jm060319f","article-title":"Semisynthetic maytansine analogues for the targeted treatment of cancer","volume":"49","author":"Widdison","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201146_bib69","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2026.201146_bib70","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","article-title":"Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2\/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers","volume":"26","author":"Cardillo","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omton.2026.201146_bib71","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: Recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omton.2026.201146_bib72","doi-asserted-by":"crossref","first-page":"19871","DOI":"10.1021\/acs.jmedchem.5c01982","article-title":"Recent Advances in Peptide Linkers for Antibody-Drug Conjugates","volume":"68","author":"Li","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201146_bib73","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib74","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib76","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201146_bib77","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib78","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/mdm451","article-title":"Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia","volume":"19","author":"Fianchi","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib80","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/sj.leu.2403901","volume":"19","author":"Amadori","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201146_bib81","first-page":"269","article-title":"Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Reinhardt","year":"2004","journal-title":"Onkologie"},{"key":"10.1016\/j.omton.2026.201146_bib82","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib83","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201146_bib85","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib86","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib87","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.3324\/haematol.2023.284409","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22(+) acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial","volume":"109","author":"Pennesi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2026.201146_bib88","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201146_bib89","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO-25-00812","volume":"43","author":"Dilawari","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.omton.2026.201146_bib91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/1535-7163.MCT-25-0437","article-title":"Anti-tumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression","volume":"25","author":"Burke","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201146_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.32009","article-title":"Near Complete Response With Trastuzumab Deruxtecan in a Teenager With Relapsing Metastatic Desmoplastic Small Round Cell Tumor","volume":"72","author":"Donze","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib93","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","article-title":"A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization","volume":"25","author":"Hashimoto","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib94","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s40262-024-01429-5","article-title":"A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population","volume":"63","author":"Zweers","year":"2024","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omton.2026.201146_bib95","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.3390\/cimb45100512","article-title":"Targeting GD2-Positive Tumor Cells by Pegylated scFv Fragment-Drug Conjugates Carrying Maytansinoids DM1 and DM4","volume":"45","author":"Kalinovsky","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.omton.2026.201146_bib96","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/1078-0432.CCR-22-0717","article-title":"Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4838(90)90139-7","article-title":"Bifunctional antibodies: concept, production and applications","volume":"1040","author":"Nolan","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omton.2026.201146_bib98","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/imm.13743","article-title":"Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics","volume":"171","author":"Sandeep","year":"2024","journal-title":"Immunology"},{"key":"10.1016\/j.omton.2026.201146_bib99","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.omton.2026.201146_bib100","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib101","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1200\/JCO.22.02200","article-title":"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse","volume":"41","author":"Hogan","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29715","article-title":"Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib103","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2026.201146_bib104","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","article-title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","volume":"60","author":"Dombret","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omton.2026.201146_bib105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib107","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMoa2214171","article-title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia","volume":"388","author":"van der Sluis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib108","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib109","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib111","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib112","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib113","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.xphs.2019.06.025","article-title":"Characterization of a Novel Bispecific Antibody With Improved Conformational and Chemical Stability","volume":"109","author":"Manikwar","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib114","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1080\/07391102.2023.2300129","article-title":"Structural and functional analysis of engineered antibodies for cancer immunotherapy: insights into protein compactness and solvent accessibility","volume":"43","author":"Saini","year":"2025","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.omton.2026.201146_bib115","article-title":"Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors","volume":"20","author":"Wang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.omton.2026.201146_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1376096","article-title":"Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies","volume":"15","author":"Mohan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib117","article-title":"RUBY(R) - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties","volume":"16","author":"Nyesiga","year":"2024","journal-title":"Mabs-Austin"},{"key":"10.1016\/j.omton.2026.201146_bib118","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41467-020-16231-7","article-title":"Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics","volume":"11","author":"Froning","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201146_bib119","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201146_bib120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001238","article-title":"Novel cytokine-antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma","volume":"8","author":"Chu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib121","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2510829122","article-title":"EVOLVE platform, a trispecific T cell engager with integrated CD2 costimulation, for the treatment of solid and hematologic tumors","volume":"122","author":"Sergeeva","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib122","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood.2022016243","article-title":"A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL","volume":"140","author":"Zhao","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib123","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201146_bib124","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/cpt.3588","article-title":"Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell Lymphoma","volume":"117","author":"Li","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib125","doi-asserted-by":"crossref","DOI":"10.1080\/1547691X.2025.2537408","article-title":"Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates","volume":"22","author":"Koch","year":"2025","journal-title":"J. Immunotoxicol."},{"key":"10.1016\/j.omton.2026.201146_bib126","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13742","article-title":"First-in-human study of JNJ-67571244, a CD33 x CD3 bispecific antibody, in relapsed\/refractory acute myeloid leukemia and myelodysplastic syndrome","volume":"17","author":"Narayan","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib127","article-title":"Therapeutic cancer vaccines for pediatric malignancies: advances, challenges, and emerging technologies","volume":"3","author":"Olsen","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201146_bib128","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with beta-glucan for high-risk neuroblastoma in second or later remission","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib129","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.20.01892","article-title":"Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression","volume":"39","author":"Cheung","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamaoncol.2022.5999","article-title":"Effect of Oral beta-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial","volume":"9","author":"Cheung","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib131","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201146_bib132","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.omton.2026.201146_bib133","first-page":"127","article-title":"Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity","volume":"21","author":"Gross","year":"1989","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.omton.2026.201146_bib134","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain","volume":"178","author":"Hwu","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201146_bib135","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib136","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib137","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib138","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201146_bib140","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib141","article-title":"First-Ever CAR T-cell Therapy Approved in U.S.","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201146_bib142","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib143","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1200\/JCO-25-00668","article-title":"Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma","volume":"43","author":"Neelapu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib144","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed\/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib146","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib147","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib148","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578717","article-title":"Neurotoxicity associated with chimeric antigen receptor T-cell therapy","volume":"407","author":"Wronski","year":"2025","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.omton.2026.201146_bib150","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib151","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib152","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib153","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008659","article-title":"Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers","volume":"12","author":"Gargett","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib154","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib155","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201146_bib156","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1158\/1078-0432.CCR-25-0089","article-title":"D3-GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma and small cell lung cancer","volume":"31","author":"Giudice","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib157","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/2326-6066.CIR-24-0975","article-title":"GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15\/IL21 Exhibit Enhanced Activity against Neuroblastoma","volume":"13","author":"Okada","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib158","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccell.2021.12.005","article-title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","volume":"40","author":"Heitzeneder","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201146_bib159","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib160","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41586-025-09539-1","article-title":"Proteotoxic stress response drives T cell exhaustion and immune evasion","volume":"647","author":"Wang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib161","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41577-025-01221-x","article-title":"Regulators of CD8(+) T cell exhaustion","volume":"26","author":"Sun","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib162","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155518","article-title":"Potential alternatives to alphabeta-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review","volume":"262","author":"Tang","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.omton.2026.201146_bib164","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tips.2015.11.004","article-title":"Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors","volume":"37","author":"Harris","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"\u201cNatural\u201d killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib166","first-page":"112","article-title":"Surface characteristics of the human K (killer) lymphocyte","volume":"55","author":"Eremin","year":"1977","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib167","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib168","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib169","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2567.2007.02573.x","article-title":"In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection","volume":"121","author":"Zhang","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.omton.2026.201146_bib170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12253-008-9073-5","article-title":"Late immune recovery in children treated for malignant diseases","volume":"14","author":"Kovacs","year":"2008","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib171","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/bjh.14570","article-title":"Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma","volume":"177","author":"Shah","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omton.2026.201146_bib172","doi-asserted-by":"crossref","DOI":"10.3791\/2540","article-title":"Expansion, purification, and functional assessment of human peripheral blood NK cells","author":"Somanchi","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omton.2026.201146_bib173","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.70023","article-title":"Ex Vivo IL-15-Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia","volume":"100","author":"Mestre-Duran","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2026.201146_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-70958-7","article-title":"Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed\/refractory neuroblastomas post autologous hematopoietic stem cell transplantation","volume":"14","author":"Mohseni","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201146_bib175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000176","article-title":"Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial","volume":"8","author":"Nguyen","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib176","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40425-019-0564-6","article-title":"A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia","volume":"7","author":"Nguyen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib177","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib178","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13287-021-02277-x","article-title":"Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future","volume":"12","author":"Lamb","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib179","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jcyt.2025.04.064","article-title":"Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy","volume":"27","author":"Caporale","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.omton.2026.201146_bib180","article-title":"Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma","volume":"33","author":"Chu","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib181","article-title":"Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma","volume":"32","author":"Luo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100032","article-title":"CD38-CAR human NK cells in combination with ATRA enhance cytotoxicity against CD38-expressing hematologic malignancies","volume":"1","author":"Troy","year":"2024","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.omton.2026.201146_bib183","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib184","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202503249","article-title":"gammadelta T cells are the prime antitumoral T cells in pediatric neuroblastoma","volume":"8","author":"Castenmiller","year":"2025","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omton.2026.201146_bib185","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108343","article-title":"The increased IL-17-producing gammadeltaT cells promote tumor cell proliferation and migration in neuroblastoma","volume":"211","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib187","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1158\/1078-0432.CCR-14-1371","article-title":"Promising cell-based immunotherapy using gamma delta T cells: together is better","volume":"20","author":"Dechanet-Merville","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2057012","article-title":"Dissecting the cellular components of ex vivo gammadelta T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials","volume":"11","author":"Jonus","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201146_bib189","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1593804","article-title":"Ex vivo expanded patient-derived gammadelta T-cell immunotherapy enhances neuroblastoma tumor regression in a murine model","volume":"8","author":"Zoine","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201146_bib190","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/14712598.2023.2245326","article-title":"Oncolytic virotherapies for pediatric tumors","volume":"23","author":"Gross","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib191","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1330868","article-title":"TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model","volume":"15","author":"Schober","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201146_bib192","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/1078-0432.CCR-22-1961","article-title":"The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4\/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma","volume":"29","author":"Schober","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib193","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/1078-0432.CCR-24-3721","article-title":"Measles Oncolytic Virus as an Immunotherapy for Recurrent\/Refractory Pediatric Medulloblastoma and Atypical Teratoid\/Rhabdoid Tumor: Results from PNOC005","volume":"31","author":"Yu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib194","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/neuonc\/noae066","article-title":"The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models","volume":"26","author":"de la Nava","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.18632\/oncotarget.28343","article-title":"Intraventricular immunovirotherapy; a translational step forward","volume":"14","author":"Bernstock","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201146_bib196","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3171\/2023.12.PEDS23404","article-title":"The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study","volume":"33","author":"Barkley","year":"2024","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.omton.2026.201146_bib197","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib198","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib199","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41591-023-02730-9","article-title":"Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E\/R4: phase 1\/2 trial results","volume":"30","author":"Mendell","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib201","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib203","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201146_bib204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.omto.2019.10.003","article-title":"Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1","volume":"15","author":"Zhu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201146_bib205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001292","article-title":"Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy","volume":"9","author":"Khalique","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib206","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41417-021-00350-4","article-title":"CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201146_bib207","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177810","article-title":"Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes","volume":"12","author":"Marino","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201146_bib208","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.3","article-title":"Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy","volume":"2","author":"Huang","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201146_bib209","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s40425-019-0807-6","article-title":"Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples","volume":"7","author":"Scott","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40425-019-0505-4","article-title":"Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager","volume":"7","author":"de Sostoa","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib211","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib212","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41417-019-0110-1","article-title":"Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers","volume":"27","author":"Barlabe","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201146_bib213","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/2326-6066.CIR-17-0314","article-title":"Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager","volume":"6","author":"Wing","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib214","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1890","article-title":"Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics","volume":"8","author":"Cripe","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omton.2026.201146_bib215","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V90.9.3691","article-title":"The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells","volume":"90","author":"Deininger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib216","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib217","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib218","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib219","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib220","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cam4.383","article-title":"Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04","volume":"4","author":"Manabe","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201146_bib221","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib222","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib223","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.omton.2026.201146_bib224","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib225","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","article-title":"Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia","volume":"26","author":"Hijiya","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib226","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib227","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib228","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood.2023023502","article-title":"Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia","volume":"143","author":"Chalandon","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib229","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1200\/JCO.23.00897","article-title":"Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054\/COG AAML1921","volume":"42","author":"Brivio","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib230","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41375-025-02578-7","article-title":"Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1(T315I) treated with at least 2 prior TKIs: Phase 1 final results","volume":"39","author":"Hochhaus","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201146_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164102","article-title":"Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML","volume":"13","author":"Millot","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201146_bib232","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ajh.27528","article-title":"Treatment-Free Remissions in Children With Chronic Myeloid Leukemia (CML): A Prospective Study From the Tata Memorial Hospital (TMH) Pediatric CML (pCML) Cohort","volume":"100","author":"Roy Moulik","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2026.201146_bib233","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib234","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib235","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","article-title":"Protein Kinase Inhibitors","year":"2012"},{"key":"10.1016\/j.omton.2026.201146_bib236","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115308","article-title":"Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions","volume":"220","author":"Desai","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib238","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14740338.2023.2274426","article-title":"Safety of current treatment options for NTRK fusion-positive cancers","volume":"22","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.omton.2026.201146_bib239","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112984","article-title":"Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSe-crizotinib trial","volume":"191","author":"Brugieres","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib241","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1515\/jpem-2024-0281","article-title":"Selpercatinib prior to radioactive iodine for pediatric papillary thyroid carcinoma","volume":"37","author":"Chiu","year":"2024","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.omton.2026.201146_bib242","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib243","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/thy.2024.0495","article-title":"Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma","volume":"35","author":"Hamidi","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.omton.2026.201146_bib244","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28317","article-title":"Cabozantinib for relapsed neuroblastoma: Single institution case series","volume":"67","author":"Perisa","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib245","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27077","article-title":"A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group","volume":"65","author":"Chuk","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib246","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib247","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1200\/JCO.23.00045","article-title":"Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology","volume":"41","author":"Weiss","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib248","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial","volume":"21","author":"Weiss","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib249","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1158\/1078-0432.CCR-23-0257","article-title":"Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent\/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study","volume":"29","author":"Casanova","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib250","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cam4.5044","article-title":"A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results","volume":"12","author":"Attia","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201146_bib251","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib252","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.23.00558","article-title":"Phase II Trial of Dabrafenib Plus Trametinib in Relapsed\/Refractory BRAF V600-Mutant Pediatric High-Grade Glioma","volume":"41","author":"Hargrave","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib253","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib254","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4","volume":"27","author":"Fangusaro","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib255","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma","volume":"41","author":"Bouffet","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib256","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12885-024-11820-x","article-title":"LOGGIC\/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"24","author":"van Tilburg","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib257","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib258","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib259","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib260","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib261","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2021005164","article-title":"Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia","volume":"5","author":"McCall","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201146_bib262","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ajh.26447","article-title":"Gilteritinib clinical activity in relapsed\/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors","volume":"97","author":"Numan","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.omton.2026.201146_bib263","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1158\/1078-0432.CCR-15-1998","article-title":"A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"22","author":"Cooper","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib264","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-78024-8","article-title":"Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia","volume":"10","author":"Moreira-Nunes","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201146_bib265","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00280-011-1618-8","article-title":"Efficacy and pharmacokinetic\/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer","volume":"68","author":"Carol","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201146_bib266","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/pbc.24653","article-title":"Spindle assembly checkpoint gene expression in childhood adrenocortical tumors (ACT): Overexpression of Aurora kinases A and B is associated with a poor prognosis","volume":"60","author":"Borges","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib267","doi-asserted-by":"crossref","first-page":"35247","DOI":"10.18632\/oncotarget.6208","article-title":"Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma","volume":"6","author":"Bogen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201146_bib268","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/neuonc\/noac151","article-title":"Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid\/rhabdoid tumor","volume":"25","author":"Upadhyaya","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib269","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":"Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study","volume":"18","author":"Mosse","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib270","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/COC.0000000000000543","article-title":"Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors","volume":"42","author":"Shah","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib271","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.neo.2018.08.002","article-title":"Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma","volume":"20","author":"Felgenhauer","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201146_bib272","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.neo.2021.05.003","article-title":"The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53","volume":"23","author":"Yi","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201146_bib273","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1097\/MPH.0000000000001416","article-title":"Targeted Polo-like Kinase Inhibition Combined With Aurora Kinase Inhibition in Pediatric Acute Leukemia Cells","volume":"41","author":"Jayanthan","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib274","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11060-018-2755-2","article-title":"The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells","volume":"137","author":"Zumbar","year":"2018","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065408","article-title":"MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4\/6 Inhibitors' Efficacy in Neuroblastoma Cells","volume":"24","author":"De Rosa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib276","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/1535-7163.MCT-21-0598","article-title":"Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma","volume":"21","author":"Pribnow","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201146_bib277","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.1158\/1078-0432.CCR-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib278","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.1158\/1078-0432.CCR-18-1256","article-title":"Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling","volume":"24","author":"Dowless","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib279","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.21873\/anticanres.15115","article-title":"Combination of CDK4\/6 and mTOR Inhibitors Suppressed Doxorubicin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model: A Translatable Strategy for Recalcitrant Disease","volume":"41","author":"Oshiro","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib280","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1200\/JCO.21.01152","article-title":"Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial","volume":"39","author":"Bautista","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib281","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-20-4078","article-title":"A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study","volume":"27","author":"DeWire","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib282","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","article-title":"A Phase I Study of the CDK4\/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors","volume":"23","author":"Geoerger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib283","article-title":"Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4\/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)","volume":"8","author":"Macy","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib284","doi-asserted-by":"crossref","first-page":"15207","DOI":"10.1002\/cam4.6208","article-title":"Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma","volume":"12","author":"Shulman","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2026.201146_bib285","article-title":"Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma","volume":"11","author":"Gao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib286","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ijc.32936","article-title":"Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma","volume":"147","author":"Tee","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib287","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1172\/JCI134132","article-title":"Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma","volume":"130","author":"Poon","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201146_bib288","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jpainsymman.2025.04.016","article-title":"Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase Inhibitors","volume":"70","author":"Koch","year":"2025","journal-title":"J. Pain Symptom Manage."},{"key":"10.1016\/j.omton.2026.201146_bib289","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"Broome","year":"1963","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201146_bib290","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0003-9861(64)90032-3","article-title":"Tumor Inhibitory Effect of L-Asparaginase from Escherichia Coli","volume":"105","author":"Mashburn","year":"1964","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.omton.2026.201146_bib291","first-page":"1574","article-title":"Response to highly purified L-asparaginase during therapy of acute leukemia","volume":"29","author":"Hill","year":"1969","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib292","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/224594a0","article-title":"Physicochemical studies of L-asparaginase from Erwinia carotovora","volume":"224","author":"North","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib293","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1749-6632.1990.tb18151.x","article-title":"Antitumor enzyme: polyethylene glycol-modified asparaginase","volume":"613","author":"Wada","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib294","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/1097-0142(19950301)75:5<1176::AID-CNCR2820750519>3.0.CO;2-Y","article-title":"An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia","volume":"75","author":"Ettinger","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib295","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.leu.2403351","article-title":"Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia","volume":"18","author":"Hak","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2026.201146_bib296","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib297","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib298","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib299","first-page":"591","article-title":"Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children","volume":"60","author":"Sutow","year":"1976","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.omton.2026.201146_bib300","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.19.01086","article-title":"Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331","volume":"38","author":"Maloney","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib301","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.1993.11.3.538","article-title":"Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group","volume":"11","author":"Wells","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib302","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib303","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib304","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2285::AID-CNCR10>3.0.CO;2-Q","article-title":"Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium","volume":"80","author":"Silverman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib305","first-page":"535","article-title":"All patients with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders","volume":"90","author":"Rowley","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib306","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib307","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201146_bib308","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1182\/bloodadvances.2024015180","article-title":"Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION\/HO141 trial","volume":"9","author":"Niemann","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201146_bib309","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood.2024025563","article-title":"Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation","volume":"145","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib310","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib311","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib312","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib313","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31714","article-title":"Venetoclax Alone or in Combination With Chemotherapy in Paediatric and Adolescent\/Young Adult Patients With Relapsed\/Refractory Acute Myeloid Leukaemia","volume":"72","author":"Karol","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib314","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31630","article-title":"Venetoclax Combined With Chemotherapy in Pediatric and Adolescent\/Young Adult Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"72","author":"Place","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib315","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1074\/jbc.M112.414177","article-title":"The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737","volume":"288","author":"Boiani","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201146_bib316","article-title":"Clinical Significance of TERT Promoter Mutations in Neuroblastoma","volume":"9","author":"Persaud","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib317","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/nar\/gkad1242","article-title":"METTL3 drives telomere targeting of TERRA lncRNA through m6A-dependent R-loop formation: a therapeutic target for ALT-positive neuroblastoma","volume":"52","author":"Vaid","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201146_bib318","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245732","article-title":"Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the TERT and ATRX Genes","volume":"15","author":"Djos","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201146_bib319","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gcc.20074","article-title":"Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas","volume":"41","author":"Ulaner","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib320","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/s41588-025-02296-x","article-title":"Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis","volume":"57","author":"McLoughlin","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2026.201146_bib321","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/0008-5472.CAN-24-3304","article-title":"DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer","volume":"85","author":"Kurani","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib322","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.CCR-09-2850","article-title":"The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth","volume":"16","author":"Marian","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib323","doi-asserted-by":"crossref","first-page":"6578","DOI":"10.1158\/1078-0432.CCR-13-1117","article-title":"A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112)","volume":"19","author":"Thompson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib324","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-016-2189-7","article-title":"A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study","volume":"129","author":"Salloum","year":"2016","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib325","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136653","article-title":"Targeting Telomere Biology in Acute Lymphoblastic Leukemia","volume":"22","author":"Karow","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib326","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib327","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cell.2006.09.034","article-title":"The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres","volume":"127","author":"Verdun","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201146_bib328","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1093\/nar\/gkp582","article-title":"Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway","volume":"37","author":"Rizzo","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omton.2026.201146_bib329","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.celrep.2015.10.041","article-title":"ATM and ATR Signaling Regulate the Recruitment of Human Telomerase to Telomeres","volume":"13","author":"Tong","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201146_bib330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5750","article-title":"ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156","volume":"13","author":"Koneru","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201146_bib331","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/cas.70043","article-title":"ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN-Amplified Neuroblastoma","volume":"116","author":"Lai","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.omton.2026.201146_bib332","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315242121","article-title":"ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition","volume":"121","author":"Borenas","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib333","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1158\/1078-0432.CCR-24-1047","article-title":"Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma","volume":"30","author":"Ohmura","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib334","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-23-3063","article-title":"Cell Context Is the Third Axis of Synergy for the Combination of ATR Inhibition and Cisplatin in Ewing Sarcoma","volume":"30","author":"Jess","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib335","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/neuonc\/noaf102","article-title":"The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts","volume":"27","author":"Xue","year":"2025","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib336","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110216","article-title":"ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization","volume":"38","author":"Qin","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201146_bib337","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/oncotarget.28551","article-title":"ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines","volume":"15","author":"Lozinski","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201146_bib338","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/neuonc\/noad064","article-title":"ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma","volume":"25","author":"Xie","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib339","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0042-105292","article-title":"No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3","volume":"228","author":"Wiese","year":"2016","journal-title":"Klin. P\u00e4diatr."},{"key":"10.1016\/j.omton.2026.201146_bib340","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41374-021-00700-8","article-title":"Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies","volume":"102","author":"Qi","year":"2022","journal-title":"Lab. Invest."},{"key":"10.1016\/j.omton.2026.201146_bib341","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102600","article-title":"Review: Targeting EZH2 in neuroblastoma","volume":"119","author":"Gao","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.omton.2026.201146_bib342","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-020-00868-4","article-title":"Targeting epigenetics in sarcomas through EZH2 inhibition","volume":"13","author":"Italiano","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib343","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.omton.2026.201146_bib344","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib345","doi-asserted-by":"crossref","first-page":"677","DOI":"10.18632\/oncotarget.28229","article-title":"Tazemetostat in relapsed\/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes","volume":"13","author":"Proudman","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2026.201146_bib346","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41416-020-01077-z","article-title":"First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours","volume":"123","author":"Ameratunga","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib347","article-title":"Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib\/IIa Study of PLX2853\/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer","volume":"7","author":"Duska","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib348","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-023-36976-1","article-title":"BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas","volume":"14","author":"Moreno","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201146_bib349","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/7945884","article-title":"The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma","volume":"2022","author":"Jia","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib350","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib351","first-page":"4337","article-title":"Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma","volume":"29","author":"Morris","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib352","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","article-title":"FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma","volume":"30","author":"Fallah","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib353","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5523832","article-title":"A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children","volume":"2021","author":"Jiang","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib354","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-023-01750-w","article-title":"Hypoxia and HIFs in Ewing sarcoma: new perspectives on a multi-facetted relationship","volume":"22","author":"Ceranski","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib355","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94128-1","article-title":"A hypoxia risk signature for the tumor immune microenvironment evaluation and prognosis prediction in acute myeloid leukemia","volume":"11","author":"Jiang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201146_bib356","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI91893","article-title":"Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia","volume":"128","author":"van Oosterwijk","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201146_bib357","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187206","article-title":"Immunohistochemical analysis of PDK1, PHD3 and HIF-1alpha expression defines the hypoxic status of neuroblastoma tumors","volume":"12","author":"Ognibene","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201146_bib358","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.npep.2015.10.005","article-title":"Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology","volume":"55","author":"Tilan","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.omton.2026.201146_bib359","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.24599","article-title":"Hypoxic tumor microenvironment in advanced retinoblastoma","volume":"60","author":"Sudhakar","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib360","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004828","article-title":"Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects","volume":"5","author":"Allen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201146_bib361","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/molpharm.121.000336","article-title":"Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D(2) Dopamine Receptor","volume":"100","author":"Free","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omton.2026.201146_bib362","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2019.03.014","article-title":"Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality","volume":"35","author":"Ishizawa","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201146_bib363","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib364","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201146_bib365","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.omton.2026.201146_bib366","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib367","first-page":"528","article-title":"Neoplasia in aged rats following early vitamin A deficiency","volume":"94","author":"Van Dyke","year":"1946","journal-title":"Anat. Rec."},{"key":"10.1016\/j.omton.2026.201146_bib368","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.88.1.89","article-title":"Correlation of the level of hepatic riboflavin with the appearance of liver tumors in rats fed aminoazo dyes","volume":"88","author":"Miller","year":"1948","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omton.2026.201146_bib369","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1126\/science.96.2492.322.b","article-title":"Uniformities in the Content of B Vitamins in Malignant Neoplasms","volume":"96","author":"Taylor","year":"1942","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib370","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0140-6736(49)90298-6","article-title":"Resistance to tumour growth in rats fed on vitamin-B complex","volume":"1","author":"Scott","year":"1949","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib371","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.835006","article-title":"13-cis-retinoic acid: inhibition of bladder carcinogenesis in the rat","volume":"195","author":"Sporn","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201146_bib372","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/260049a0","article-title":"Mediation of retinoic acid-induced growth and anti-tumour activity","volume":"260","author":"Chytil","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201146_bib373","first-page":"1647","article-title":"Inhibition of growth and regression of a transplantable rat chondrosarcoma by three retinoids","volume":"60","author":"Trown","year":"1976","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.omton.2026.201146_bib374","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/BF01922901","article-title":"Retinoids, a new class of compounds with prophylactic and therapeutic activities in oncology and dermatology","volume":"34","author":"Mayer","year":"1978","journal-title":"Experientia"},{"key":"10.1016\/j.omton.2026.201146_bib375","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI110450","article-title":"Retinoic acid. Inhibition of the clonal growth of human myeloid leukemia cells","volume":"69","author":"Douer","year":"1982","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omton.2026.201146_bib376","first-page":"209","article-title":"Retinoic acid-binding protein in normal tissues and experimental tumors","volume":"37","author":"Sanl","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib377","first-page":"190","article-title":"Relationship between binding affinities to cellular retinoic acid-binding protein and biological potency of a new series of retinoids","volume":"44","author":"Sani","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib378","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/1097-0142(19950815)76:4<680::AID-CNCR2820760423>3.0.CO;2-9","article-title":"all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial","volume":"76","author":"Moasser","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib379","first-page":"991","article-title":"Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients","volume":"17","author":"Toma","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib380","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1023\/A:1026579400806","article-title":"A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study","volume":"11","author":"Miller","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib381","first-page":"204","article-title":"Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial","volume":"78","author":"Chiesa","year":"2007","journal-title":"Acta Biomed."},{"key":"10.1016\/j.omton.2026.201146_bib382","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/08880019809028791","article-title":"All-trans-retinoic acid (ATRA): pediatric acute promyelocytic leukemia","volume":"15","author":"Bapna","year":"1998","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib383","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-02-0632","article-title":"All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol","volume":"100","author":"Tallman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib384","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1200\/JCO.20.03096","article-title":"Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study","volume":"39","author":"Zheng","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib385","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27542","article-title":"Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)","volume":"66","author":"Kutny","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib386","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib387","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12885-018-4280-2","article-title":"Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial","volume":"18","author":"Zhang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib388","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2016.71.6183","article-title":"Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631","volume":"35","author":"Kutny","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib389","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-017-3042-6","article-title":"Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy","volume":"96","author":"Abla","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.omton.2026.201146_bib390","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1073\/pnas.80.18.5525","article-title":"Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines","volume":"80","author":"Haussler","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib391","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-4827(83)90184-2","article-title":"Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines","volume":"148","author":"Sidell","year":"1983","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2026.201146_bib392","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2007.13.8925","article-title":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study","volume":"27","author":"Matthay","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib393","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1054\/bjoc.2000.1425","article-title":"A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy","volume":"83","author":"Kohler","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib394","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1158\/1078-0432.CCR-12-2225","article-title":"Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma","volume":"19","author":"Veal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib395","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0003-9861(58)90382-5","article-title":"[Partial anaerobiosis and radiation-sensitivity of cancer cells]","volume":"78","author":"Warburg","year":"1958","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.omton.2026.201146_bib396","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1073\/pnas.60.4.1420","article-title":"Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors","volume":"60","author":"Russell","year":"1968","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201146_bib397","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0065-2571(79)90008-6","article-title":"Cyclic AMP-mediated induction of ornithine decarboxylase in normal and neoplastic growth","volume":"17","author":"Russell","year":"1978","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.omton.2026.201146_bib398","first-page":"245","article-title":"Inhibition of phorbol ester-induced ornithine decarboxylase gene transcription by retinoic acid: a possible mechanism of antitumor promoting activity of retinoids","volume":"259","author":"Verma","year":"1988","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.omton.2026.201146_bib399","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0014-4827(84)90771-7","article-title":"Changes in inducibility of ornithine decarboxylase activity in differentiating human neuroblastoma cells","volume":"155","author":"Mattsson","year":"1984","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2026.201146_bib400","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/1097-0215(20010101)91:1<8::AID-IJC1007>3.0.CO;2-H","article-title":"Retinoic acid (RA) receptor transcriptional activation correlates with inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase (ODC) activity by retinoids: a potential role for trans-RA-induced ZBP-89 in ODC inhibition","volume":"91","author":"Dawson","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib401","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/carcin\/7.6.1019","article-title":"Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and alpha-difluoromethylornithine","volume":"7","author":"Verma","year":"1986","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.omton.2026.201146_bib402","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-4827(85)90276-9","article-title":"Inhibition of ornithine decarboxylase by retinoic acid and difluoromethylornithine in relation to their effects on differentiation and proliferation","volume":"156","author":"Jetten","year":"1985","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2026.201146_bib403","first-page":"434","article-title":"Further studies on difluoromethylornithine in African trypanosomes","volume":"59","author":"McCann","year":"1981","journal-title":"Med. Biol."},{"key":"10.1016\/j.omton.2026.201146_bib404","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00179433","article-title":"Phase I evaluation of intravenous difluoromethylornithine--a polyamine inhibitor","volume":"3","author":"Maddox","year":"1985","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.omton.2026.201146_bib405","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0005-2787(79)90031-5","article-title":"Inhibition of cytomegalovirus-stimulated human cell ornithine decarboxylase by alpha-difluoromethylornithine","volume":"564","author":"Isom","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omton.2026.201146_bib406","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ijc.2910370117","article-title":"Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone A interferon and retinoic acid","volume":"37","author":"Bregman","year":"1986","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib407","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0014-4827(88)90281-9","article-title":"Correlation between transglutaminase activity and polyamine levels in human neuroblastoma cells. Effect of retinoic acid and alpha-difluoromethylornithine","volume":"179","author":"Melino","year":"1988","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omton.2026.201146_bib408","first-page":"291","article-title":"Chemoprevention clinical trials","volume":"267","author":"Kelloff","year":"1992","journal-title":"Mutat. Res."},{"key":"10.1016\/j.omton.2026.201146_bib409","first-page":"3485","article-title":"In vivo growth inhibition of human colon carcinoma cells (HT-29) by all-trans-retinoic acid, difluoromethylornithine, and colon mitosis inhibitor, individually and in combination","volume":"20","author":"Paulsen","year":"2000","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib410","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/sj.onc.1208808","article-title":"Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells","volume":"24","author":"Wallick","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201146_bib411","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib412","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1158\/0008-5472.CAN-08-1865","article-title":"Ornithine decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling pathways via phosphorylation of both Akt\/protein kinase B and p27Kip1 in neuroblastoma","volume":"68","author":"Koomoa","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib413","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1158\/0008-5472.CAN-08-2968","article-title":"Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma","volume":"69","author":"Rounbehler","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib414","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ccr.2005.03.036","article-title":"Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation","volume":"7","author":"Nilsson","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201146_bib415","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.22.02875","article-title":"Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons","volume":"42","author":"Oesterheld","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib416","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101215","article-title":"High-dose DFMO alters protein translation in neuroblastoma","volume":"68","author":"Franson","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.omton.2026.201146_bib417","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1099","article-title":"Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma","volume":"11","author":"Gamble","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2026.201146_bib418","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2025.43.16_suppl.10001","article-title":"A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed\/refractory neuroblastoma: A Children\u2019s Oncology Group (COG) report","volume":"43","author":"Macy","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib419","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-24-1778","article-title":"Polyamine Depletion by D,L-alpha-Difluoromethylornithine Inhibits Ewing Sarcoma Metastasis by Inducing Ferroptosis","volume":"31","author":"Offenbacher","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib420","article-title":"Polyamine Biosynthetic Pathway as a Drug Target for Osteosarcoma Therapy","volume":"6","author":"Weicht","year":"2018","journal-title":"Med. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib421","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.clpt.6100109","article-title":"Future of pediatric therapeutics: reauthorization of BPCA and PREA","volume":"81","author":"Ward","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omton.2026.201146_bib422","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-024-03097-x","article-title":"Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development","volume":"19","author":"Mease","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omton.2026.201146_bib423","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2016.04.001","article-title":"Implementation of mechanism of action biology-driven early drug development for children with cancer","volume":"62","author":"Pearson","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib424","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.ejca.2009.03.007","article-title":"Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium","volume":"45","author":"Geoerger","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib425","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1177\/2168479018774533","article-title":"Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols","volume":"53","author":"Khan","year":"2019","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.omton.2026.201146_bib426","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib427","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up","volume":"6","author":"D'Angelo","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.omton.2026.201146_bib428","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study","volume":"9","author":"D'Angelo","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib429","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib430","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","article-title":"Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial","volume":"6","author":"Marabelle","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib431","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib432","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1038\/s41591-025-04032-8","article-title":"Adjuvant nivolumab and relatlimab in stage III\/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib433","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201146_bib434","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib435","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib436","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for Advanced Alveolar Soft Part Sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib437","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.21.01693","article-title":"Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621","volume":"40","author":"O'Brien","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201146_bib438","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-016-3220-6","article-title":"First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1\/Pilot Consortium","volume":"79","author":"Balis","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omton.2026.201146_bib439","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib440","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2023.0463","volume":"34","author":"Capdevila","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.omton.2026.201146_bib441","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","article-title":"FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma","volume":"30","author":"Barbato","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib442","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/bloodadvances.2022008414","article-title":"Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis","volume":"7","author":"Whitlock","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201146_bib443","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2026.201146_bib444","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib445","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201146_bib446","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa2504964","article-title":"Belzutifan for Advanced Pheochromocytoma or Paraganglioma","volume":"393","author":"Jimenez","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201146_bib447","first-page":"535","article-title":"L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia","volume":"37","author":"Ortega","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201146_bib448","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib449","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.omton.2026.201146_bib450","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood.2022016923","article-title":"Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study","volume":"141","author":"Maese","year":"2023","journal-title":"Blood"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:28:58Z","timestamp":1778272138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":450,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000226"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201146","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies in pediatric oncology: A start","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201146"}}